This Educational Series discusses the role of pharmacotherapy in obesity management in New Zealand. Obesity management medications are indicated in conjunction with a reduced-calorie diet and lifestyle interventions for patients living with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with ≥1 obesity-related complication. All the Medsafe-approved obesity management medications are effective at reducing and maintaining clinically significant weight loss, however they are not currently funded in New Zealand, resulting in unequitable access to treatment.
Please login below to download this issue (PDF)